Related references
Note: Only part of the references are listed.An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors
B. C. Goh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP
Jackie Perry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
C. Hegedus et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
Tumor suppressors and cell metabolism: a recipe for cancer growth
Russell G. Jones et al.
GENES & DEVELOPMENT (2009)
Vandetanib (Zactima, ZD6474) Antagonizes ABCC1-and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
Li-sheng Zheng et al.
PLOS ONE (2009)
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative Cancer Therapies (MDICT)
Christopher M. Booth et al.
EUROPEAN JOURNAL OF CANCER (2008)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
Henry L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
Y. Mi et al.
BRITISH JOURNAL OF CANCER (2007)
Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1α
RJ Phillips et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development
S Hsieh et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2004)
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
C Özvegy-Laczka et al.
MOLECULAR PHARMACOLOGY (2004)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
Tumor biology - Herceptin acts as an anti-angiogenic cocktail
Y Izumi et al.
NATURE (2002)
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis:: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
E Laughner et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
